Works matching AU Wu, Jianrong


Results: 241
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

    Published in:
    Pediatric Blood & Cancer, 2015, v. 62, n. 1, p. 91, doi. 10.1002/pbc.25201
    By:
    • Smith, Malcolm A.;
    • Hampton, Oliver A.;
    • Reynolds, C. Patrick;
    • Kang, Min H.;
    • Maris, John M.;
    • Gorlick, Richard;
    • Kolb, E. Anders;
    • Lock, Richard;
    • Carol, Hernan;
    • Keir, Stephen T.;
    • Wu, Jianrong;
    • Kurmasheva, Raushan T.;
    • Wheeler, David A.;
    • Houghton, Peter J.
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45

    Pharmacogenomic potential in advanced cancer patients.

    Published in:
    American Journal of Health-System Pharmacy, 2019, v. 76, n. 7, p. 415, doi. 10.1093/ajhp/zxy079
    By:
    • Nichols, Dan;
    • Arnold, Susanne;
    • Weiss, Heidi L;
    • Wu, Jianrong;
    • Durbin, Eric B;
    • Miller, Rachel;
    • Kolesar, Jill
    Publication type:
    Article
    46
    47
    48
    49
    50